Amlodipine on Blood Flow of Preovulatory Follicle in Polycystic Ovarian Patients

Effect of Amlodipine and Clomid on Blood Flow of Preovulatory Follicle in Polycystic Ovarian Patients

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02544776

Enrollment

Registered

2015-09-09

Start date

2015-01-31

Completion date

2015-09-30

Last updated

2016-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Female Infertility Associated With Anovulation

Keywords

pco, Amlodipine

Brief summary

On the basis of the current study, amlodipine seems to be a promising drug on improving uterine, ovarian blood flow, size of pre-ovulatory follicle, midluteal progesterone level and pregnancy outcome in patients with pco.

Detailed description

To know if amlodipine has vasodilator effect on ovarian ar. In pco patient.

Interventions

DRUGClomifene citrate ( clomid 50 mg )

DRUGAmlodipine

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

FEMALE

Age

20 Years to 35 Years

Healthy volunteers

Inclusion criteria

* Demographic features including females in age of ≥20 & ≤35, and BMI of ≤39. * Infertility secondary to polycystic ovary , The choice of polycystic ovary patients will be according to the Rotterdam consensus workshop (Rotterdam, 2004), and the diagnosis of polycystic ovary by ultrasonography will be made according to Adams et al. criteria which are the most often cited (Adams et al., 1985).The Rotterdam criteria as follows: * Oligo- or anovulation. * Clinical and/or biochemical signs of hyper androgynism * The presence of polycystic ovaries on ultrasound scan. Ultrasound findings of enlarged ovaries with multiple small cysts (10-12 or more of 2-9 mm in diameter) scattered around the periphery and highly echogenic stroma

Exclusion criteria

* Including other causes of infertility diagnosed during infertility work up. * Patients refused to participate or to continue study. * Also, hepatic, cardiac, and hypotensive patients will be excluded from the study.

Design outcomes

Primary

Measure	Time frame	Description
change in ovarian artery perfusion	day number five and day number 9 of menstrual cycle	peak systolic velocity ( psv ) measured by doppler u/s

Secondary

Measure	Time frame	Description
Number of mature follicle	day 14 of menstrual cycle	by vaginal u/s
endometrial thickening	day number five and day number 9 of menstrual cycle	by vaginal u/s

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026